Abstracts

Population exposure to marijuana and illicit drugs is increasing while exposure to prescription pain relievers is decreasing in the United States. Black JC, Severtson SG, Dart RC, Iwanicki JL.

Changes in substance use behaviors among those who use opioid analgesics. Severtson SG, Black JC, Iwanicki JL, Dart RC.

Effects of the COVID-19 pandemic on new cases of Drug Diversion in the United States. College on Problems of Drug Dependence Annual Meeting. • Bernal K, Severtson S, Buttram M, Dart RC, Iwanicki J.

Ketamine non-medical use versus medical use in the United States’ general population. College on Problems of Drug Dependence Annual Meeting. • Krause A, Czizik A, Black JC, Dart RC, Iwanicki J.

Non-medical use of XTAMPZA ER: motivation, methods, and perceptions of tampering. PAINWeek 2022, Las Vegas, NV. • Black JC, Burkett H, Rockhill KM, Iwanicki JL, Dart RC.

Cross-sectional study of tampering in an abuse-deterrent formulation of an extended-release opioid in a treatment center population. PAINWeek 2022, Las Vegas, NV. Jewell J, Black JC, Ellis M, Olsen H, Iwanicki JL, Dart RC.

Differences in the severity of medical outcomes of exposures reported to poison centers involving XTAMPZA ER and other opioid analgesics. PAINWeek 2022, Las Vegas, NV. Severtson SG, Black JC, Iwanicki JL, Dart RC.

Association between per capita prescribing and abuse of tapentadol and other opioids among individuals entering treatment for opioid use disorders. PAINWeek 2022, Las Vegas, NV. Severtson SG, Czizik AM, Ellis M, Black JC, Iwanicki JL, Dart RC.

Buprenorphine diversion in the US: National diversion rates and qualitative findings from law enforcement. International Society of Addiction Medicine Annual Meeting. Valletta, Malta.. Buttram ME, Ellis MS, Stivers Y, Kurtz SP

Reductions in prescribing following legislative intervention to make gabapentin a controlled substance at the state level in the U.S. Lisbon Addictions 2022. Lisbon, Portugal. Buttram ME, Severtson SG, Beekman K, Stivers Y, Ellis MS. ORAL PRESENTATION

Evaluation of prescription stimulant use in the United States: Understanding unique behavioral profiles. American Public Health Association Annual Meeting. Boston, MA. November 2022. Rockhill KM, Olson RR, Iwanicki JL, Black JC. POSTER

Prescription vs Illicit Opioid Abuse Among Healthcare workers Seeking Addiction Treatment
Bernal K, Lenahan W, Severtson S, Kreider S, Iwanicki JL
Clin Toxicol. 2021

Mortality of buprenorphine and methadone in the United States 2010-2017
Black JC, Bau GE, Iwanicki JL, Dart RC
College on Problems of Drug Dependence Annual Meeting, Virtual. June 2021. POSTER

Difference in mortality assessment due to the definition of overdose when using death certificate text
Black JC, Bau G, McCoy R, et al.
Society for Epidemiologic Research Annual Meeting. Virtual. June 2021. ORAL PRESENTATION

Prevalence of Pharmaceutical Anti-Depressant Non-Medical Use in the United States
Black J, Forber A, Iwanicki JL, Dart RC
American Public Health Association Annual Meeting. Denver, CO (Hybrid). October 2021.

Online Discussion and Sales of Tapentadol and Oxycodone in Australia
Black JC, Margolin ZR, Bau GE, Iwanicki JL, Dart RC
IMIA. Virtual. August 2021

Non-Medical Use and Diversion of XTAMPZA ER in General Adult Population
Black JC, Rockhill KM, Severtson SG, Iwanicki JL, Dart RC
PAINWeek 2021, Las Vegas, NV (Hybrid). September 2021.

Prevalence of non-medical drug use by drug type and state, Survey of Non-Medical Use of Prescription Drugs Program (NMURx)
Malaga A, et al.
American Public Health Association Annual Meeting. Denver, CO (Hybrid). October 2021.

Assessment of online content discussing initiation, switching, and cessation of pharmaceutical opioids
Margolin ZR, Olson R, Black JC, Wogenstahl K, Dart RC
College on Problems of Drug Dependence Annual Meeting, Virtual. June 2021. POSTER

COVID-19’s impact on substance abuse treatment and medication assisted therapy
Olson HA, Haynes CM, Grundy D, Severtson SG, Ellis M, Parrino M, Iwanicki JL
College on Problems of Drug Dependence Annual Meeting, Virtual. June 2021. POSTER

CO Shifts in black market drug transactions during the COVID-19 pandemic: analysis of crowd-sourced transaction reports
Olson R, May K et al.
College on Problems of Drug Dependence Annual Meeting, Virtual. June 2021. POSTER

Drug use surveillance measures through a public-access online dashboard
Rockhill K, Forber A, Rapp-Olsen A, Black JC, Dart RC
Council of State and Territorial Epidemiologists Annual Conference, Virtual. June 2021.

Abuse of Tapentadol Compared to Other Atypical Opioids among Individuals Entering Treatment for Opioid Use Disorders
Severtson SG, Gurrola MC, Iwanicki JL, Dart RC
PAINWeek 2021, Las Vegas, NV (Hybrid). September 2021.

Diversion and Street Price of XTAMPZA ER Relative to Other Prescription Opioids
Severtson SG, Margolin ZR, Iwanicki JL, Dart RC
PAINWeek 2021, Las Vegas, NV (Hybrid). September 2021.

Abuse and Misuse of XTAMPZA ER Relative to Other Opioid Analgesics
Severtson SG, Olsen HA, Iwanicki JL, Dart RC
PAINWeek 2021, Las Vegas, NV (Hybrid). September 2021.

Estimates of the number of adults in the United States who only obtain prescription opioids through diversion
Severtson SG, Rockhill K, Black JC, Iwanicki JL
American Public Health Association Annual Meeting. Denver, CO (Hybrid). October 2021

Prevalence of non-medical use of over-the-counter medications by healthcare providers.
Rapp-Olsson M, Black JC, Iwanicki JL.
Clin Toxicol. 2020; 58(11):1086-1087.

Changes in prescription opioid exposures reported to poison centers following the emergence of the COVID-19 pandemic.
Severtson SG, Gurrola M, Gardiner T, Dart RC, Iwanicki JL.
Clin Toxicol. 2020; 58(11):1220.

Reductions in the percentage of buprenorphine products dispensed in child-resistant unit-dose packaging associated with increases in...
Severtson SG, Margolin ZR, Trubetskoy K, Iwanicki JL, Dart RC
APHA Annual Meeting. Virtual. October 2020

Perception of XTAMPZA® ER and other abuse-deterrent opioid formulations on the internet
Black JC, Margolin ZR, Iwanicki JL, Dart RC
PAINWeek 2020, Virtual. September 2020

The diversion and street price of XTAMPZA® ER relative to other prescription opioids
Severtson SG, Margolin ZR, May K, Iwanicki JL, Dart RC
PAINWeek 2020, Virtual. September 2020.

Abuse of tapentadol among individuals entering treatment for opioid use disorder
Severtson SG, Olsen H, Iwanicki JL, Dart RC
PAINWeek 2020, Virtual. September 2020.

Abuse of XTAMPZA® ER relative to other opioid analgesics
Severtson SG, Olsen H, Iwanicki JL, Dart RC
PAINWeek 2020, Virtual. September 2020.

Effects of item order randomization in an online national drug use survey
Amioka EC, Black JC, Iwanicki JL, Dart RC
Joint Statistical Meetings’ 2020 Annual Meeting. Virtual conference. August 2020

Non-medical use and injection use of prescription opioids in Spain in the Non-Medical Use of Prescription Drug (NMURx) national survey
Fonseca F, Torrens M, Iwanicki JL, Haynes CM, Dart RC
CPDD Annual Meeting, Virtual. June 2020

Emerging stimulant mortality trends by active ingredient
Black JC, Bau GE, Iwanicki JL, Dart RC
CPDD Annual Meeting, Virtual. June 2020

Methods for identifying careless responses in online survey data
Amioka EC, Black JC, Forber A, Rockhill KM, Dart RC
JSM. Denver, CO. July 2019

Abuse of pregabalin and gabapentin in the US
Asomaning K, Bau GE, Severtson SG, Rockhill K, Martire D, Dart RC
CPDD. San Antonio, TX. June 2019

Analysis of Drug Mentions with Involvement for prescription stimulants
Black JC, McCoy RH
NAPHSIS. Columbus, OH. June 2019
ORAL PRESENTATION

Method for selecting calibration weights in a non-probability epidemiological survey
Black JC, Forber A, Rockhill KM, Amioka EC, May KP, Dart RC
JSM. Denver, CO. July 2019

Perception of XTAMPZA® ER and other abuse-deterrent opioid formulations on the internet
Black JC, Margolin ZR, Iwanicki JL, Dart RC
PAINWeek 2019. Las Vegas, NV. September 2019

Non-medical use of prescription GABA analogues (gabapentin and pregabalin) in Europe in the Non-Medical Use of Prescription Drugs (NMURx) National Surveys
Bonney CF et al.
EAPCCT. Naples, Italy. May 2019

Diverging Epidemics: Shifting patterns of opioid use between treatment-seeking opioid users in Canada and the United States
Ellis MP
CSAM. Halifax, Nova Scotia. October 2019
ORAL PRESENTATION

Differences in the pattern and prevalence of non-medical use of prescription benzodiazepines, gamma-aminobutyric acid (GABA) analogues and stimulants in Europe
Hockenhull J et al.
EAPCCT. Naples, Italy. May 2019

Regional variation in non-medical use of benzodiazepines in the UK
Hockenhull J, Wood DM, Haynes CM, Black JC, Rockhill K, Dart RC, Dargan PI
EAPCCT. Naples, Italy. May 2019

Cannabis use and high risk substance use behaviors in the United States non-medical use of prescription drugs (NMURx) national survey
Iwanicki JI, Black JC, Haynes CM, Dart RC
NACCT. Nashville, TN. September 2019

Non-medical use of prescription stimulants in Europe in the Non-Medical Use of Prescription Drugs (NMURx) National Surveys
Iwanicki JL et al.
EAPCCT. Naples, Italy. May 2019

Pilot of a novel online survey to assess risk-benefit profile of pain treatments
Iwanicki JL, Magtanong R, Amioka E, May KP, Black JC, Flarity K, Dart RC
MHSRS. Kissimmee, FL. August 2019

Prevalence of non-medical use of prescription opioids in Canada in 2017
Iwanicki JL, Black JC, May KP, Sproule B, Dart RC
CCSA. Ottawa, Ontario. November 2019

Report building: SAS and Microsoft Word VBA made easy
Kreider S
JSM. Denver, CO. July 2019
ORAL PRESENTATION

Regional variability in intentional exposures to prescription medications in France and Italy
LeRoy SJ, Margolin ZR, Lagrotteria JJ, Severtson SG, Mégarbane B, Villa A, Sesana F, Iwanicki JL, Dart RC
EAPCCT. Naples, Italy. May 2019

Examining prescription opioid diversion cases and cases involving illicitly manufactured opioids in Canada
Levi-Minzi MA, Margolin Z, Wogenstahl K, Martin G, Buttram ME, Kurtz SP
CPDD. San Antonio, TX. June 2019

Utilizing the internet as a public health surveillance medium: outcomes from the RADARS® System Web Monitoring Program
Margolin ZR, Wogenstahl KW, Black JC, Olson RA, Dart RC
JSM. Denver, CO. July 2019

Cross-border trafficking of prescription oxycodone products manufactured in Canada
May KP, Schwarz J, Iwanicki JL
CCSA. Ottawa, Ontario. November 2019

Regional estimates for prevalence of non-medical use of prescription opioids in Canada
Nugent E, Black JC, Dart RC
CPHA. Ottawa, Canada. April 2019
ORAL PRESENTATION

Kratom use and high risk substance use behaviors in the United States non-medical use of prescription drugs national survey
Schimmel J et al.
ACEP. Denver, Co. October 2019
ORAL PRESENTATION

Prevalence of illicit drug and non-medical prescription drug use among pregnant women in the United States
Seidel Halmo L, Rockhill K, Black JC, Iwanicki JI
NACCT. Nashville, TN. September 2019

Abuse of XTAMPZA® ER is rare relative to other opioid analgesics
Severtson SG, Wogenstahl K, Cicero TJ, Iwanicki JL, Dart RC
PAINWeek 2019. Las Vegas, NV. September 2019

Associations between legal and illegal distribution of prescription medications in Canada
Severtson SG, Margolin ZR, Wogenstahl KW, Iwanicki JL, Levi-Minzi MA, Martin G, Buttram ME, Dart RC
CCSA. Ottawa, Ontario. November 2019

Changes in the prevalence of methamphetamine abuse among individuals entering medication-assisted treatment programs
Severtson SG et al.
AATOD. Orlando, FL. October 2019

Misclassification bias may contribute to overestimates of use of specific opioid products
Severtson SG, Iwanicki JL, Kurtz SP, Dart RC
CPDD. San Antonio, TX. June 2019

Pediatric, self-harm cases comprise a large proportion of intentional exposures to methylphenidate reported to participating poison centres
Severtson SG et al.
EAPCCT. Naples, Italy. May 2019

The diversion and street price of XTAMPZA® ER relative to other prescription opioids
Severtson SG, Wogenstahl K, Buttram ME, Kurtz S, Iwanicki JL, Dart RC
PAINWeek 2019. Las Vegas, NV. September 2019

Non-medical use of codeine products in Canada
Sproule B, Black JC, Dart RC
CPDD. San Antonio, TX. June 2019

Law enforcement reports of increasing methamphetamine use and associations with the opioid epidemic
Buttram M, Kurtz SP
CPDD. San Diego, CA. June 2018

Trend-in-trend method to analyze abuse of new and low volume opioids in the community setting
Dasgupta N, Schwarz J, Dart RC
SER. Baltimore, MD. June 2018

Substantial increases in methamphetamine use among a national sample of treatment-seeking opioid users
Ellis MS, Kasper ZA, Cicero TJ
CPDD. San Diego, CA. June 2018
ORAL PRESENTATION

Regional variations in opioid use patterns among treatment-seeking opioid users in Central and Western Canada
Ellis MP, Kasper ZA, Cicero TJ
CSAM. Vancouver, British Columbia. October 2018

Intentional opioid exposures with benzodiazepine co-ingestants in the US and Europe as reported to the RADARS® System Global Toxicosurveillance Network
Fischer LJ et al.
EAPCCT. Bucharest, Romania. June 2018

Increase in drug injectors in Southeast U.S. and in rural-suburban counties among entrants to opioid treatment programs
Fong C, Rosenblum A
AATOD. New York, NY. March 2018

Alprazolam misuse among young people in the United Kingdom
Hockenhull J, Amioka E, Black JC, Haynes CM, Wood DM, Dart RC, Dargan PI
NACCT. Chicago, IL. October 2018

Gabapentin and pregabalin abuse among EUROPAD subjects
Iwanicki J, Hennessy M, Severtson SG, McBride K, Schwarz J, Scherbaum N, Hill D, Guareschi M, Dart RC, Maremmani I
CPDD. Sandiego, CA. June 2018

Gabapentinoid abuse among EUROPAD subjects
Iwanicki JL, Hennessy M, Severtson SG, McBride KE, Schwarz J, Scherbaum N, Hill D, Guareschi M, Dart RC, Maremanni I
NACCT. Chicago, IL. October 2018

Assessment of tapentadol API abuse liability with the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS®) System Poison Center Program
Iwanicki JL et al.
PAINWeek. Las Vegas, NV. September 2018

Content validity of a survey to evaluate the benefits and risks associated with treatments for pain
Iwanicki JL, Magtanong R, Black J, Dart RC
PAINWeek. Las Vegas, NV. September 2018

The diversion of non-scheduled psychoactive prescription drugs in the United States
Kurtz SP, Buttram ME, Margolin ZR, Wogenstahl K
ISAM. Busan, South Korea. November 2018
ORAL PRESENTATION

Unintentional pediatric exposures to prescription medications in Europe as reported to the RADARS® System Global Toxicosurveillance Network
Margolin ZR et al.
EAPCCT. Bucharest, Romania. June 2018

Reported chronic pain and overdose by patients enrolling in opioid dependence treatment in France and the United Kingdom
McBride K et al.
AATOD. New York, NY. March 2018

Use of treatment history to identify drug differences in patients entering medication-assisted maintenance substance abuse treatment programs in France and the United Kingdom
Olsen H et al.
AATOD. New York, NY. March 2018

Comparing prescription opioids, methadone, and heroin rates from the Treatment Episode Data Set to the RADARS® System Treatment Center Programs
Olsen HA, Severtson SG, Schwarz J, Ellis M, Cicero TJ, Dart RC
CPDD. San Diego, CA. June 2018

Comparing prescription opioid use among heroin abusers using the RADARS® System EUROPAD Program
Olsen HA et al.
EUROPAD. Krakow, Poland. May 2018

Evaluating surveillance indicators of prescription and illicit drug use using the RADARS® System Survey of Non-Medical Use of Prescription Drugs Program
Rockhill K et al.
CSTE. West Palm Beach, FL. June 2018
ORAL PRESENTATION

Mosaic approach for monitoring Healthy People 2020 objectives: A substance abuse surveillance system
Rockhill K, Bau GE, Ellis MS, Cicero TJ, Dart RC
APHA. San Diego, CA. November 2018
ORAL PRESENTATION

Hierarchical clustering of mental health disorder diagnoses based on opioid non-medical use frequency
Swanson JD, Black JC, Haynes CM, Rockhill K, May KP, Amioka E, Dart RC
AAAP. Bonita Springs, FL. December 2018

Benzodiazepines use “to get high” in patients admitted for addiction treatment in Spain
Torrens M, Fonseca F, Farré M, McBride K, Maremmani I, Guareschi M, Dart RC
CPDD. San Diego, CA. June 2018

Comparing intentional exposure rates between stimulants in the RADARS® System poison center data
Benallo MA, Kreider SE, Green JL, Dart RC
NACCT. Vancouver, BC. October 2017

An online survey on misuse of benzodiazepines and ‘Z drugs’ in Singapore
Chan WL, Wood DM, Haynes CM, Rockhill KM, Green JL, Dargan PI
EAPCCT. Basel, Switzerland. May 2017

Non-medical use of loperamide in the United Kingdom
Dargan PI, Haynes CM, Wood DM, May KP, Rockhill KM, Green JL
EAPCCT. Basel, Switzerland. May 2017

Case review of opioid-induced thrombotic thrombocytopenic purpura (TTP) from pharmacovigilance and poison centers
Dasgupta N, Schwarz J, Dart RC
ICPE Annual Meeting. Montreal, Quebec. August 2017

The opioid epidemic in Canada: trends in diversion of commonly abused prescription drugs in Ontario
Dziadkowiec O et al.
NIDA International Forum at CPDD Annual Meeting. Montreal, Quebec. June 2017

Age of Misuse Exposures Reported by the Global Toxicosurveillance Network (GTNet)
Fischer LJ et al.
EAPCCT. Basel, Switzerland. May 2017
ORAL PRESENTATION

Patterns of cannabis use in patients admitted for addiction treatment in Spain
Fonseca F, Torrens M, Farré M, McBride KE, Maremmani I, Guareschi M, Green JL, Dart RC
NIDA International Forum at CPDD Annual Meeting. Montreal, Quebec. June 2017

Increased risk of problematic drug use among adults with chronic pain
Haynes CM, Rockhill KM, May KP, Black JC, Dart RC, Green JL
PAINWeek 2017. Las Vegas, NV. September 2017

Relationship between poison center opioid exposure and mortality rates and National Vital Statistics System mortality rates
Iwanicki JL, Margolin ZR, Severtson SG, Dart RC.
EAPCCT. Basel, Switzerland. May 2017
ORAL PRESENTATION

Five program system for post-marketing surveillance of prescription drug misuse
Iwanicki JL, Haynes CM, Sproule B, Kurtz SP, Cicero TJ, Dasgupta N, Dart RC, Green JL
CCSA Issues of Substance Conference. Calgary, Alberta. November 2017

Systematic surveillance of illicitly manufactured fentanyl cases initiated by law enforcement
Kurtz SP, Buttram ME
CPDD Annual Meeting. Montreal, Quebec. June 2017
ORAL PRESENTATION

The opioid epidemic in Canada: trends in diversion of commonly abused prescription drugs in Canada
Levi-Minzi MA et al.
CCSA Issues of Substance Conference. Calgary, Alberta. November 2017

Prevalence of non-medical use of prescription drugs in the United States in 2016
May KP, Haynes CM, Rockhill KM, Margolin ZR, Dart RC, Green JL
CPDD Annual Meeting. Montreal, Quebec. June 2017

Cross-border trafficking of prescription oxycodone products manufactured in Canada
May KP, Rosen T, Dasgupta N, Green JL, Dart RC
CPS Annual Meeting. Halifax, NS. May 2017

Non-medical use and abuse of drugs used for opioid agonist therapy in Canada
May KP, Rockhill KM, Eldred-Skemp NA, Haynes CM, Sproule B, Dart RC, Green JL
CSAM Annual Meeting and Scientific Conference. Niagara Falls, Ontario. October 2017

Prevalence of non-medical use of prescription drugs in Canada
May KP, Rockhill KM, Sproule B, Eldred-Skemp NA, Haynes CM, Dart RC, Green JL
CSAM Annual Meeting and Scientific Conference. Niagara Falls, Ontario. October 2017

Reported chronic pain and overdose by patients enrolling in opioid dependence treatment
McBride K et al.
CSAM Annual Meeting and Scientific Conference. Niagara Falls, Ontario. October 2017

Prevalence of illicit drug use: Survey of Non-Medical Use of Prescription Drugs Program compared to NSDUH
Rockhill KM, Haynes CM, May KP, Margolin ZR, Dart RC, Green JL
CPDD Annual Meeting. Montreal, Quebec. June 2017

The Great Lakes effect: discovering hot spots for rates of diversion of prescription opioids within Ontario, Canada
Rosen T et al.
NIDA International Forum at CPDD Annual Meeting. Montreal, Quebec. June 2017

Racial/ethnic trends of heroin and non-medical use of prescription opioids among entrants to opioid treatment programs, 2005-2016
Rosenblum A, Pouget E, Fong C
CPDD Annual Meeting. Montreal, Quebec. June 2017

Past month prevalence of chewing, snorting, smoking and injecting prescription opioid tablets and capsules among individuals entering substance abuse treatment
Severtson SG et al.
CPS Annual Meeting. Halifax, NS. May 2017

Rate of Nucynta® ER intentional abuse calls to poison centers are lower than ER oxycodone and ER oxymorphone
Severtson SG, Vosburg SK, Green JL, Dart RC
ICOO. Boston, MA. June 2017

Rate of Nucynta® ER intentional abuse calls to poison centers are lower than ER oxycodone and ER oxymorphone
Severtson SG, Vosburg SK, Green JL, Dart RC
PAINWeek 2017. Las Vegas, NV. September 2017

Abuse liability of tapentadol is significantly lower than other schedule II opioids
Vosburg SK, Severtson SG, Green JL, Kurtz SP, Dart RC
ICOO. Boston, MA. June 2017

Comparison of prevalence of illicit drug use in the UK Survey of the NMURx Program and the annual Crime Survey for England and Wales 2014-2016
Wood DM, Green JL, Haynes CM, Rockhill KM, Dargan PI
EAPCCT. Basel, Switzerland. May 2017

Characterizing opioid and benzodiazepine abuse as reported by patients entering medication-assisted substance abuse treatment programs in Europe
Bau G et al.
AATOD National Conference. Baltimore, MD. October 2016

Severe adverse events associated with intentional abuse via an unintended route for fentanyl patches compared to other schedule II opioids
Benallo M, McDaniel HA, Green JL, Dart RC
NACCT. Boston, MA. September 2016

Increasing abuse of gabapentin and pregabalin as reported to US poison centers 2006 through 2014
Bucher-Bartelson B, Bau G, Severtson SG, Green JL, Dart RC
CPDD Annual Meeting, Palm Springs, CA. June 2016

Trends in benzodiazepine and opioid analgesic misuse and mortality reported to poison centers across the United States
Calcaterra SL et al.
SGIM Annual Meeting. Hollywood, FL. May 2016

Online survey on prescription medicine misuse: what is the evidence for prescription opioid misuse in Singapore?
Chan WL, Wood DM, Besharat AC, McDaniel HA, Green JL, Dargan PI
EAPCCT. Madrid, Spain. May 2016

Monitoring internet postings for mentions of an extended-release (ER) hydrocodone formulation with abuse-deterrent properties
DeVeaugh-Gess A et al.
CPDD Annual Meeting. Palm Springs, CA. June 2016

Intentional abuse cases mentioning prescription opioid products following the hydrocodone rescheduling
Fischer LJ, Severtson SG, Green JL, Dart RC, RADARS System Poison Center Group
NACCT. Boston, MA. September 2016

Patterns of prescription drug use and misuse in Spain: The European opioid treatment patient survey
Fonseca F et al.
(NIDA) International Forum at CPDD Annual Meeting. Palm Springs, CA. June 2016

Accidental unsupervised ingestions of Nucynta® ER in children less than six years-old: Frequency and risk of severe outcomes
Green JL, Kreider SED, Severtson SG, Dart RC
PAINWeek 2016. Las Vegas, NV. September 2016

Tampering and medical outcomes in poison center abuse and misuse Nucynta® ER exposures
Green JL, Le Lait MC, Severtson SG, Dart RC
PAINWeek 2016. Las Vegas, NV. September 2016

Prescription Opioid Death Rates are Greater for Females than Males
Iwanicki JL, Le Lait MC, Severtson SG, Bucher-Bartelson B, Dart RC
American College of Medical Toxicology Annual Scientific Meeting. Huntington Beach, CA. March 2016

Abuse of immediate release opioid analgesics as compared to extended release formulations in the United States
Iwanicki JL, McDaniel HA, Severtson SG, Green JL, Dart RC
EAPCCT. Madrid, Spain. May 2016
ORAL PRESENTATION

International perspective on prescription benzodiazepine exposures reported by poison centres in the Global Toxicosurveillance Network
Johnson DJD et al.
NACCT. Boston, MA. September 2016

Tracking the trends over time of global adult human exposures to benzodiazepines and opioids reported to poison centres in the Global Toxicosurveillance Network
Johnson DJG et al.
EAPCCT. Madrid, Spain. May 2016

Tracking the trends over time of unintentional pediatric exposures to benzodiazepines and opioids reported to poison centres in the Global Toxicosurveillance Network
Johnson DJG et al.
EAPCCT. Madrid, Spain. May 2016

Intertwined Non-pharmaceutical Fentanyl Epidemics in Canada and the United States
Kurtz SP, Buttram ME
GAC. Venice, Italy, October 2016

A characterization of first-time enrollees and repeated enrollees entering medication-assisted substance abuse treatment programs
Margolin ZR et al.
EUROPAD. Leiden, Netherlands. May 2016

Reported route and source of primary drugs of abuse by patients entering medication-assisted substance abuse treatment in Europe
McBride KE et al.
EUROPAD Conference. Leiden, Netherlands. May 2016

Characterizing opioid and benzodiazepine abuse as reported to opioid treatment programs in the United States
McDaniel HA, Goodman E, McBride K, Green JL, Rosenblum A, Dart RC
AATOD National Conference. Baltimore, MD. October 2016

Racial/ethnic differences in primary drug used among entrants to opioid treatment programs over time
Pouget ER, Fong C, Rosenblum A
AATOD National Conference. Baltimore, MD. October 2016

Routes of administration of Tapentadol products as reported to poison centers
Severtson SG, Bucher-Bartelson B, Green JL, Dart RC
Annual Scientific Meeting of the APS. Austin, TX. May 2016

Impact of unit dose packaging on unintentional pediatric buprenorphine exposures
Wang GS, Bau G, Severtson SG, Green JL, Dart RC
American Public Health Association Annual Meeting. Denver, CO. October 2016

Characterization of marijuana use in college students as reported to an online survey
Wang GS, Besharat AC, Le Lait MC, Haynes C, Dart RC, Roosevelt G
EAPCCT. Madrid, Spain. May 2016

Unintentional exposures to prescription opioid analgesics among children under age six: trends over time
Wang GS, McDaniel HA, Bucher Bartelson B, Green JL, Dart RC
PAS Meeting. Baltimore, MD. May 2016
ORAL PRESENTATION

Prescription opioid abuse or misuse in pregnancy using poison center data
Warrick BJ, Sycamore K, Holbrook BD, Smolinske S, Seifert SA, Bau G, Bucher Bartelson B, Severtson SG, Green JL, Dart RC
NACCT. Boston, MA. September 2016

Trends in Tramadol Use and Abuse reported to the Ontario Poison Centre
Austin E, Thompson M, Hudson H, Bernabeo D, Johnson DJG, Dart RC
CPS 36th Annual Scientific Meeting
Charlottetown, PEI. May 2015

Trends Over Time in Pop Rates of Intentional Misuse and Self-Harm Mentions with Buprenorphine, Methadone, and Oxycodone as Reported to PCs in DE, IT & UK
Bucher Bartelson B et al.
EAPCCT
St Julian's, Malta. May 2015
ORAL PRESENTATION

Medical outcomes associated with unintended routes of prescription opioid abuse
Bucher Bartelson B, Le Lait MC, Dart RC, Roland CL, Masters ET, Mardekian J, Green JL
PAINWeek 2015
Las Vegas, NV. September 2015

Online survey on prescription medicine misuse: what is the evidence for misuse of benzodiazepines and ‘Z drugs’ in Singapore?
Chan WL et al.
APAMT
Perth, Australia. December 2015
ORAL PRESENTATION

Prescription Opioids: Reported Reasons for Non-Medical Use in an Online National Survey in the UK
Dargan PI, Martinez EM, Besharat AC, Green JL, Wood DM
EAPCCT
St. Julian's, Malta. May 2015

Chronic Pain and Non-Medical Use of Opioids, Benzodiazepines, and Pregabalin in an Online National Survey in the United Kingdom
Dargan PI et al.
EAPCCT
St Julian's, Malta. May 2015
ORAL PRESENTATION

Monitoring the Street Price of Diverted Opioids in Canada with StreetRx.com
Dart RC, Goodman EM, McBride K, Margolin Z, Dasgupta N, Menone C, Green JL, Iwanicki JL
CCSA Conference
Montreal, Quebec. November 2015

Chronic pain and non-medical use of opioids, benzodiazepines, and pregabalin in the United Kingdom
Dart RC, Dargan PI, Wood DM, Besharat AC, Goodman EM, Iwanicki JL, Green JL
PAINWeek2015
Las Vegas, NV. September 2015

Prevalence of Serious Adverse Events by Injection or Inhalation of Prescription Stimulants
Fischer LJ, Severtson SG, Dart RC, RADARS System Poison Center Group
NACCT
San Francisco, California. October 2015

Characterization of Chronic Pain in College Students as Reported to an Online Survey
Fix CM, Besharat AC, Dart RC
NACCT
San Francisco, California. October 2015

Reductions in prescription opioid abuse among enrollees into opioid treatment programs
Fong C, Rosenblum A
AATOD National Conference
Atlanta, GA. March 2015

An online national survey and the Crime Survey for England and Wales: are the data comparable?
Green JL, Dargan PI, Wood DM, Besharat AC, Martinez EM, Dart RC
CPDD Annual Meeting
Phoenix, AZ. June 2015

Non-Medical Use of Benzodiazepines and Opioids: an Online National Survey in the United Kingdom
Green JL, Besharat AC, Goodman EM, Bucher Bartelson B, Wood DM, Dargan PI
ICPE
Boston, MA. August 2015

Prescription Opioid Exposures and Outcomes among Older Adults
Hatten BW, West NA, Severtson SG, Green JL, Dart RC
SAEM National Conference
San Diego, CA. May 2015
ORAL PRESENTATION

Chronic Pain and Non-Medical Use of Prescription Opioids in a United Kingdom National Survey
Iwanicki JL, Besharat AC, Goodman EM, Dargan PI, Wood DM, Dart RC, Green JL
CCSA Conference
Montreal, Quebec. November 2015

Prescription opioid death rates are greater for females than males
Iwanicki JL, Le Lait MC, Severtson SG, Bucher-Bartelson B, Dart RC
CPDD Annual Meeting
Phoenix, AZ. June 2015
ORAL PRESENTATION

Abuse deterrent reformulation of controlled release oxycodone is associated with persistently declining rates of abuse and diversion by both oral and non-oral routes
Iwanicki JL et al.
PAINWeek 2015
Las Vegas, NV. September 2015

Age and gender distribution among patients entering treatment for opioid addiction
Lavery SA et al.
AATOD National Conference
Atlanta, GA. March 2015

Rates of Suicide Involving Prescription Opioids Before, During and After the Great Recession
Lavery SA, Le Lait MC, West NA, Dart RC, RADARS System Poison Center Group
NACCT
San Francisco, CA. October 2015

Trends of suspected suicide involving prescription opioids by 4 United States regions
Lavery SA, West NA, Le Lait MC, Dart RC, RADARS System Poison Center Group
NACCT
San Francisco, CA. October 2015
ORAL PRESENTATION

Reduced Street Price and Quantity Discounts for Diverted Extended Release OxyContin and Opana Following Crush Resistant Reformulation
Lebin JA et al.
SAEM National Conference
San Diego, CA. May 2015
ORAL PRESENTATION

Non-medical Use of Prescription and Illicit Drugs in Public versus Private Colleges & Universities
Margolin Z, Besharat AC, Nelson SK, West NA, Bucher Bartelson B, Green JL, Dart RC
NACCT
San Francisco, CA. October 2015

Decrease in Exposure Calls to Poison Centers: A Look at Opioid and Stimulant Drug Classes Over time By Age Group
Marquess SA, McDaniel HA, West NA, Dart RC, RADARS System Poison Center Group
NACCT
San Francisco, CA. October 2015

A comparison of attempted suicide rates by methylphenidate exposure in adult and adolescent populations
McRae EM, Le Lait MC, West N, Dart RC
CPDD Annual Meeting
Phoenix, AZ. June 2015
ORAL PRESENTATION

Comparative Rates of Mortality and Severe Medical Effect Among Commonly Prescribed Opioid Analgesics
Murphy DL et al.
SAEM National Conference
San Diego, CA. May 2015
ORAL PRESENTATION

Non-Dermal Routes Used in Fentanyl Patch Intentional Exposures
Nickless JR, Le Lait MC, West NA, Coulter MS, Dart RC, RADARS System Poison Center Group
NACCT
San Francisco, CA. October 2015

Reductions in prescription opioid abuse among enrollees into opioid treatment programs
Rosenblum A, Fong C, Matusow H, Parrino M, Maxwell-Taylor C
CPDD Annual Meeting
Phoenix, AZ. June 2015
ORAL PRESENTATION

Abuse and diversion of buprenorphine/naloxone oral film relative to other buprenorphine formulations
Severtson SG et al.
AAAP Annual Meeting
Huntington Beach, CA. December 2015

Unintentional exposures to buprenorphine/naloxone tablets and oral film among children less than six years old; October 2010 through June 2015
Severtson SG et al.
AAAP Annual Meeting
Huntington Beach, CA. December 2015

Transborder trafficking of prescription opioids in Canada and the United States
Severtson SG, Besharat AC, Green JL, Dasgupta N, Ellis MS, Cicero TJ, Dart RC
CPS 36th Annual Scientific Meeting
Charlottetown, PEI. May 2015

Use of opiates to get high in patients seeking opiate addiction treatment: Europe and the U.S.
Somaini L et al.
AATOD National Conference. Atlanta, GA. March 2015

Pregabalin, Gabapentin and Baclofen: Sources of Drug Acquisition for Non-Medical Use in an Online National Survey in the UK
Wood DM, Besharat AC, Dargan PI, Martinez EM, Green JL
EAPCCT
St. Julian's, Malta. May 2015

Benzodiazepines and ‘Z Drugs’: Reported Reasons for Non-Medical Use in an Online National Survey in the UK
Wood DM, Besharat AC, Martinez EM, Green JL, Dargan PI
EAPCCT
St. Julian's, Malta. May 2015

Perception of Prescription Drug Safety in an Online National Survey in the United Kingdom
Wood DM, Dargan PI, Besharat AC, Martinez EM, Green JL
EAPCCT
St Julian's, Malta. May 2015

An analysis of the abuse and associated deaths of immediate release opioid analgesics as compared to extended release formulations in the United States
Bebarta VS, Severtson SG, Green JL, Dart RC
NACCT. New Orleans, LA. October 2014

Pediatric serious adverse events after exposure to immediate and extended release opioids
Brown KR, Le Lait MC, Dart RC
NACCT. New Orleans, LA. October 2014

Age differences in intentional abuse cases mentioning hydrocodone products versus schedule II opioids
Fischer LJ, Severtson SG, Dart RC
NACCT. New Orleans, LA. October 2014

New Trends of Prescription Drug Use in Spain
Fonseca, F, Green, JL, Maremmani, I, Touzeau, D, Walcher, S, Deruvo, G, Somaini, L, Martinez, D, Rossi, P, Torrens, M
EUROPAD. Glasgow, Scotland, UK. May 2014

Buprenorphine/naloxone pediatric ingestion: exposure rates differ between film and tablet formulations
Green JL, Martinez EH, Severtson SG, Dart RC, Lavonas EJ
ACMT. Phoenix, AZ. March 2014

Buprenorphine/naloxone abuse and diversion: film rates are less than tablet rates
Green JL, Martinez EM, Severtson SG, Cicero TJ, Kurtz SP, Rosenblum A, Surratt HL, Dart RC, Lavonas EJ
ACMT. Phoenix, AZ. March 2014

Buprenorphine/naloxone abuse and diversion: film rates are less than tablet rates
Green JL, Martinez EM, Severtson SG, Cicero TJ, Kurtz SP, Rosenblum A, Surratt HL, Dart RC, Lavonas EJ
ASAM. Orlando, FL. April 2014

Buprenorphine/naloxone pediatric ingestion: exposure rates differ between film and tablet formulations
Green JL, Martinez EM, Severtson SG, Dart RC, Lavonas EJ
ASAM. Orlando, FL. April 2014

Global impact of prescription opioid misuse: Europe and US
Green JL et al.
CPDD. San Juan, Puerto Rico. June 2014

Buprenorphine/Naloxone pediatric ingestion: exposure rates differ between film and tablet formulations
Green JL, Martinez EM, Severtson SG, Dart RC, Lavonas EJ
CPDD. San Juan, Puerto Rico. June 2014

Buprenorphine/Naloxone abuse and diversion: film rates are less than tablet rates
Green JL, Martinez EM, Severtson SG, Cicero TJ, Kurtz SP, Rosenblum A, Surratt HL, Dart RC, Lavonas EJ
CPDD. San Juan, Puerto Rico. June 2014

Prescription opioid misuse in Europe: from opioid treatment programs to poison centres
Green JL et al.
EAPCCT. Brussels, Belgium. May 2014

Global Toxicosurveillance Network (GTNet): Characterizing prescription opioid exposures reported to european poison centres
Green JL et al.
EAPCCT. Brussels, Belgium. May 2014

Factors associated with non-medical use of stimulants among college students
Lavery SA, Le Lait MC, Severtson SG, West NA, Dart RC
NACCT. New Orleans, LA. October 2014

The role of tapentadol ER in the illicit market for opioid analgesics in the United States
Le Lait C, Severtson G, Surratt H, Burke J, Bebarta V, Dart RC
APS. Tampa, FL. May 2014

The street prices of immediate release and extended release tapentadol are lower than other Schedule II opioid tablets/capsules
Le Lait MC, Severtson SG, Dasgupta N, Green JL, Hall A, Dart RC
CPDD. San Juan, Puerto Rico. June 2014

European opiate addiction treatment programs: poly-opioid users are different than other patients seeking treatment
Martinez EM et al.
EUROPAD. Glasgow, Scotland, UK. May 2014

Gender differences in patients entering treatment programs in Europe
Martinez EM et al.
EUROPAD. Glasgow, Scotland, UK. May 2014

European patients entering opioid addiction treatment whose primary drug is heroin differ from those whose primary drug is another opioid
Martinez EM et al.
EUROPAD. Glasgow, Scotland, UK. May 2014

Use of treatment history to identify drug use differences in European patients
McBride KE, Martinez EM, Guareschi M, Touzeau D, Walcher S, Deruvo G, Somaini L, Fonseca F, Green JL, Dart RC, Maremmani I
EUROPAD. Glasgow, Scotland, UK. May 2014

Reformulation of extended release oxymorphone: changes in intentional abuse exposures before and after introduction of tamper resistant formulation
Severtson G, Le Lait C, Green J, Dart R
APS. Tampa, FL. May 2014

Regional concentrations of Opana® ER abuse before and after introduction of a tamper resistant formulation in 2012
Severtson SG, Le Lait MC, Green JL, Dart RC
CPDD. San Juan, Puerto Rico. June 2014

Diversion of Opana ER declined following introduction of a tamper resistant formulation
Severtson SG, Bucher Bartelson B, Green JL, Dart RC
ICOO. Boston, MA. June 2014

Trends among older adults in intentional prescription opioid exposure calls to poison centers
West NA, Severtson SG, Green JL, and Dart RC
NACCT. New Orleans, LA. October 2014

Diversion and illicit sale of extended release tapentadol in the United States
West NA, Le Lait MC, Surratt H, Burke JJ, Kurtz SP, Dasgupta N, Bebarta VS, Dart RC
PAINWeek. Las Vegas, NV. September 2014

Analysis of abuse of buprenorphine transdermal delivery system (Butrans®) using data from the RADARS® System Poison Center Program
Wiegand TJ, Le Lait CMC, Green JL, Dart RC
ASAM. Orlando, FL. April 2014